PK Pharma Consult SRL
Ouverture de faillitePK Pharma Consult reported total assets of 29,707 € at the end of the 2023 financial year (annual accounts filed with the NBB on 17 Jul 2024).
The score of PK Pharma Consult shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2023
Change 2021 → 2023: Equity -37 % Total assets -54 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
PK Pharma Consult's annual accounts
Filed annual accounts
- Year ended 31 Dec 2023filed on 17 Jul 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 24 Jul 2022
PK Pharma Consult's financial analysis
- Solvency99.4%sector median: 50.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PK Pharma Consult
PK Pharma Consult's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0750.549.277
- VAT number
- BE0750549277
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 10 Jul 2020
- Registered office
- 4530 Villers-le-Bouillet
- Latest accounts
- 2023 · filed on 17 Jul 2024
- Activity
- Business and other management consultancy activities (NACE 70200)
PK Pharma Consult (SRL) has been based in Villers-le-Bouillet since 2020, active in: business and other management consultancy activities. For 2023, it reports a net loss of 11,965 € and equity of 29,516 €; its revenue is not published. Its solvency stands at 99.4%, above the median of its sector (50.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to PK Pharma Consult
Companies in the same business, of comparable size and area, outside its group.
- Biscay Consulting Business and other management consultancy activities Uccle · balance sheet 29,702 €
- Symabo Business and other management consultancy activities Rochefort · balance sheet 29,699 €
- V-PowerPipe Business and other management consultancy activities Antwerp · balance sheet 29,740 €
- NK Associates Business and other management consultancy activities Genappe · balance sheet 29,755 €
- VIA Consulting Business and other management consultancy activities Walhain · balance sheet 29,756 €
- Gangou Business and other management consultancy activities Forest · balance sheet 29,759 €
- P.Droogers Coaching Activities Business and other management consultancy activities Ghent · balance sheet 29,768 €
- Next2you Business and other management consultancy activities Braine-le-Château · balance sheet 29,774 €
Frequently asked questions about PK Pharma Consult
What is the revenue of PK Pharma Consult?
PK Pharma Consult files its accounts in a format where revenue is optional: it is not published for 2023.
What is the VAT number of PK Pharma Consult?
In Belgium, the VAT number is the company number prefixed with BE: BE0750549277 for PK Pharma Consult, if the company is VAT-registered. Its company number (CBE) is 0750.549.277.
Where is the registered office of PK Pharma Consult?
According to the CBE register, the registered office of PK Pharma Consult is in 4530 Villers-le-Bouillet.
What is the equity of PK Pharma Consult?
At the close of the 2023 financial year, the equity of PK Pharma Consult amounts to 29,516 €, a solvency of 99.4% of total assets.
Who manages PK Pharma Consult?
The register lists 2 active mandates at PK Pharma Consult. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PK Pharma Consult
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →